GLP-1 Cardiovascular Trial Results
| Trial | Drug | Population | Key Finding |
|---|---|---|---|
| LEADER | Liraglutide | Type 2 diabetes + CVD | 13% reduction in MACE |
| SUSTAIN-6 | Semaglutide | Type 2 diabetes + CVD | 26% reduction in MACE |
| SELECT | Semaglutide (Wegovy) | Obesity + CVD (no diabetes) | 20% reduction in MACE |
| SURPASS-CVOT | Tirzepatide | Type 2 diabetes + CVD | Ongoing |
Cardiovascular Benefits and Coverage
The cardiovascular benefits of GLP-1 drugs strengthen the clinical case for coverage — particularly for high-risk patients with established cardiovascular disease. A 20% reduction in major cardiovascular events (heart attack, stroke, cardiovascular death) translates to significant reductions in catastrophic claims. For high-risk patients, GLP-1 drugs may be cost-effective even at $1,000/month.
Risk Stratification
IQ Insight
Risk stratification — identifying high-risk patients who are most likely to benefit from GLP-1 cardiovascular benefits — is a key component of GLP-1 coverage strategy. Patients with established cardiovascular disease, diabetes, and obesity are the highest-risk group and the most likely to benefit from GLP-1 therapy. Prioritizing GLP-1 coverage for this group maximizes clinical value and ROI.